Following the J.P. Morgan Healthcare Conference and other parallel meetings in San Francisco, it’s time to reflect on some of the significant deals secured last week.
Alto Neuroscience and Kyverna Therapeutics are following in the footsteps of CG Oncology, Metagenomi and Arrivent in seeking initial public offerings this year.
The company said it has not seen any supply issues so far due to Red Sea shipping disruptions, a top executive told Reuters ahead of the World Economic Forum (WEF) on Monday.
As JPM week drew to a close, Lilly CEO David Ricks discussed what he sees in store for the biopharma industry.
The strategic acquisition provides Roche access to Carmot’s portfolio, which notably includes three lead molecules, all GLP-1 analogues, currently in the advanced stages of clinical trials for obesity and type 2 diabetes. It also positions the company on par with other industry leaders in the realm of GLP-1 analogues, such as Novo Nordisk, Eli Lilly and others.
Dropping the potential Cytokinetics buy runs contrary to Novartis’ recent dealmaking frenzy, which included the acquisition of Calypso and three research collaborations.
Several experts on a panel Wednesday at JPM’s Biotech Showcase expressed positive attitudes for the coming year on the investment side, with the industry showing “signs of life”.
A new study published in the BMJ found strong financial ties between the pharmaceutical industry and physicians serving as panelists and task force members of the DSM-5.
Pharmaceutical executives from Amgen to Pfizer are plotting to break into the lucrative obesity market by developing or cutting deals to acquire better drugs that will compete with Novo Nordisk’s Wegovy and Zepbound from Eli Lilly .
The claims allege that the drugmaker’s tenofovir, an antiretroviral used in Gilead’s older HIV drugs, caused kidney, tooth, or bone damage to patients, and that Gilead knew its tenofovir-based drugs which were still in development, were safer.
